SE8903003D0 - NOVEL MEDICAL USE - Google Patents

NOVEL MEDICAL USE

Info

Publication number
SE8903003D0
SE8903003D0 SE8903003A SE8903003A SE8903003D0 SE 8903003 D0 SE8903003 D0 SE 8903003D0 SE 8903003 A SE8903003 A SE 8903003A SE 8903003 A SE8903003 A SE 8903003A SE 8903003 D0 SE8903003 D0 SE 8903003D0
Authority
SE
Sweden
Prior art keywords
medical use
novel medical
thioredoxin
interferons
immunoglobulins
Prior art date
Application number
SE8903003A
Other languages
Swedish (sv)
Inventor
N A Ros
Original Assignee
Astra Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astra Ab filed Critical Astra Ab
Priority to SE8903003A priority Critical patent/SE8903003D0/en
Publication of SE8903003D0 publication Critical patent/SE8903003D0/en
Priority to IL95583A priority patent/IL95583A0/en
Priority to IE323390A priority patent/IE903233A1/en
Priority to CA002065454A priority patent/CA2065454A1/en
Priority to GR900100679A priority patent/GR1001151B/en
Priority to HU92821A priority patent/HUT62932A/en
Priority to AU64336/90A priority patent/AU641942B2/en
Priority to PCT/SE1990/000578 priority patent/WO1991004320A1/en
Priority to DD90343919A priority patent/DD298056A5/en
Priority to JP2512956A priority patent/JPH05500216A/en
Priority to EP90913906A priority patent/EP0489113A1/en
Priority to PT95284A priority patent/PT95284A/en
Priority to NO920911A priority patent/NO920911D0/en
Priority to FI921058A priority patent/FI921058A0/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0036—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on NADH or NADPH (1.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/44—Oxidoreductases (1)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y108/00—Oxidoreductases acting on sulfur groups as donors (1.8)
    • C12Y108/01—Oxidoreductases acting on sulfur groups as donors (1.8) with NAD+ or NADP+ as acceptor (1.8.1)
    • C12Y108/01008—Protein-disulfide reductase (1.8.1.8), i.e. thioredoxin

Abstract

The use of thioredoxin in the treatment of B lymphocytic leukemia and certain other malignant diseases. The enzyme can be used either alone or in combination with co-factors such as anti-immunoglobulins, interferons or interleukin 1,2,3, or 4.
SE8903003A 1989-09-12 1989-09-12 NOVEL MEDICAL USE SE8903003D0 (en)

Priority Applications (14)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (en) 1989-09-12 1989-09-12 NOVEL MEDICAL USE
IL95583A IL95583A0 (en) 1989-09-12 1990-09-04 Pharmaceutical compositions comprising thioredoxin
IE323390A IE903233A1 (en) 1989-09-12 1990-09-06 Novel medical use
EP90913906A EP0489113A1 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
AU64336/90A AU641942B2 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
GR900100679A GR1001151B (en) 1989-09-12 1990-09-10 Novel pharmaceutical use
HU92821A HUT62932A (en) 1989-09-12 1990-09-10 Process for producing pharmaceutical compositions comprising thioredoxin
CA002065454A CA2065454A1 (en) 1989-09-12 1990-09-10 Use of thioredoxin in the treatment of malignantly transformed cells in animals and man
PCT/SE1990/000578 WO1991004320A1 (en) 1989-09-12 1990-09-10 The use of thioredoxin in the treatment of malignantly transformed cells in animals and man
DD90343919A DD298056A5 (en) 1989-09-12 1990-09-10 DRUG
JP2512956A JPH05500216A (en) 1989-09-12 1990-09-10 Novel medical applications
PT95284A PT95284A (en) 1989-09-12 1990-09-11 NEW METHOD OF TREATMENT OF MALIGNANT DISEASES WITH TIOREDOXIN
NO920911A NO920911D0 (en) 1989-09-12 1992-03-06 APPLICATION OF TIOREDOXIN FOR TREATMENT OF ANIMAL TRANSFORMED CELLS IN ANIMALS AND HUMANS
FI921058A FI921058A0 (en) 1989-09-12 1992-03-11 ANVAENDNING AV THIOREDOXIN VID BEHANDLING AV ELAKARTADE TRANSFORMADE CELLER I DJUR OCH MAENNISKA.

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE8903003A SE8903003D0 (en) 1989-09-12 1989-09-12 NOVEL MEDICAL USE

Publications (1)

Publication Number Publication Date
SE8903003D0 true SE8903003D0 (en) 1989-09-12

Family

ID=20376862

Family Applications (1)

Application Number Title Priority Date Filing Date
SE8903003A SE8903003D0 (en) 1989-09-12 1989-09-12 NOVEL MEDICAL USE

Country Status (12)

Country Link
EP (1) EP0489113A1 (en)
JP (1) JPH05500216A (en)
AU (1) AU641942B2 (en)
CA (1) CA2065454A1 (en)
DD (1) DD298056A5 (en)
FI (1) FI921058A0 (en)
GR (1) GR1001151B (en)
HU (1) HUT62932A (en)
IE (1) IE903233A1 (en)
PT (1) PT95284A (en)
SE (1) SE8903003D0 (en)
WO (1) WO1991004320A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7744877B2 (en) 1992-11-13 2010-06-29 Biogen Idec Inc. Expression and use of anti-CD20 Antibodies
CA2149329C (en) 1992-11-13 2008-07-15 Darrell R. Anderson Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma
US5985261A (en) * 1996-06-28 1999-11-16 National Jewish Medical And Research Center Use of thioredoxin-like molecules for induction of MnSOD to treat oxidative damage
CA2274116C (en) * 1996-12-06 2009-05-05 Garth Powis Use, of an inhibitor of thioredoxin, for inhibiting tumor growth
US6689775B2 (en) 1999-06-03 2004-02-10 Arizona Board Of Regents, Acting On Behalf Of The University Of Arizona Uses of thioredoxin
US5919657A (en) * 1997-04-09 1999-07-06 Incyte Pharmaceuticals, Inc. Nucleic acids encoding human thioredoxin protein; related reagents
US7585645B2 (en) 1997-05-27 2009-09-08 Sembiosys Genetics Inc. Thioredoxin and thioredoxin reductase containing oil body based products
BR9907990A (en) 1998-01-30 2000-10-24 Genesense Technologies Inc Sequence of oligonucleotides complementary to the thioredoxin or thioredoxin reductase genes and methods of using them to modulate cell growth
EP1112084B2 (en) 1998-08-11 2012-04-25 Biogen Idec Inc. Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody
WO2000027428A1 (en) 1998-11-09 2000-05-18 Idec Pharmaceuticals Corporation Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody
US8557244B1 (en) 1999-08-11 2013-10-15 Biogen Idec Inc. Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody
EP1332212A2 (en) * 2000-08-25 2003-08-06 Curagen Corporation Proteins and nucleic acids encoding same
US7195766B2 (en) 2002-09-10 2007-03-27 National Jewish Medical And Research Center Product and process for liquefaction of mucus or sputum
JP6672139B2 (en) 2013-03-15 2020-03-25 オアプロ セラピューティクス インコーポレイテッドＯｒｐｒｏ Ｔｈｅｒａｐｅｕｔｉｃｓ，Ｉｎｃ． Composition for normalization of mucus viscosity

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2633295B2 (en) * 1987-06-12 1997-07-23 味の素株式会社 Gene encoding human ADF

Also Published As

Publication number Publication date
GR1001151B (en) 1993-05-24
WO1991004320A1 (en) 1991-04-04
DD298056A5 (en) 1992-02-06
JPH05500216A (en) 1993-01-21
EP0489113A1 (en) 1992-06-10
AU6433690A (en) 1991-04-18
FI921058A0 (en) 1992-03-11
IE903233A1 (en) 1991-03-27
AU641942B2 (en) 1993-10-07
CA2065454A1 (en) 1991-03-13
PT95284A (en) 1991-08-14
HU9200821D0 (en) 1992-05-28
GR900100679A (en) 1992-01-20
HUT62932A (en) 1993-06-28

Similar Documents

Publication Publication Date Title
SE8903003D0 (en) NOVEL MEDICAL USE
ATE358176T1 (en) HUMAN DNASE
ES2062355T3 (en) PHARMACEUTICAL COMPOSITION INCLUDING LORATADINE, IBUPROPHEN AND PSEUDOEFEDRINE.
CA2075060A1 (en) Novel vehicle gases and their use in medical preparations
DE69328550T2 (en) USE OF FULLEREN DERIVATIVES IN DIAGNOSTIC AND / OR THERAPEUTIC AGENTS
DK0751959T3 (en) Modified polypeptides with increased biological activity
FR2584388B1 (en) COMPOSITION BASED ON CERIC OXIDE, ITS PREPARATION AND USES THEREOF
DE69017874D1 (en) EPROM arrangement with metal source connections and their manufacture.
IL75133A0 (en) Derivatives of glycerophosphocholine and glycerophosphoethanolamine,their preparation and their use
NO871053D0 (en) USE OF SUBSTITUTED N-TRIKLORMETYLTIODIKARBOKSIMIDER IN COMBINATION WITH N, N [-substituted BIS (2,4-diamino-s-triazine-6-YL) -OLIGOSULFIDER In vulcanizable KAUTSJUKBLANDINGER AND SUCH KAUTSJUKBLANDINGER.
DE69230798D1 (en) RECOMBINANT IMMUNTOXINE
NZ230155A (en) N-2,3-butadienyl-n"-substituted-triamindalkanes and alkenes, and pharmaceutical compositions
ATE58639T1 (en) APPETITE SUPPRESSIVE AND ANTI-GASTRITIS COMPOSITION.
FI830523A0 (en) ANTI-INFLAMMATORY OCH / ELLER SMAERTA LINDRANDE 2,3-DIARYL-5-HALOTIOFENER
NO894008L (en) WOOD PRESERVANT AND PROCEDURE FOR TREATMENT OF RETIREMENT WITH THE SAME.
FR2355505A1 (en) Acetamido-deoxy:gluco:pyranosyl-acetyl-alanyl-iso:glutamine - useful as immunological adjuvant
DE3881099T2 (en) ACRYLIC RUBBER, COMPOSITION OF ACRYLIC RUBBER AND ITEMS OF CROSS-LINKED ACRYLIC RUBBER.
ES2061566T3 (en) MONOCLONAL ANTIBODIES AGAINST PROTEIN E7 OF HUMAN PAPILOMAVIRUS TYPE 16, PROCEDURE FOR ITS PREPARATION, AS WELL AS ITS USE.
ZA849576B (en) 1,7-diphenyl-3-methyllaza-7-cyano-8-methylnonane for use in the treatment of diseases
IL84040A (en) Monoclonal antibodies against ifn-omega,their preparation and their use in the purification and detection of ifn-omega
ATE69549T1 (en) PRODUCTS CONTAINING GALLOPAMIL AND PRAZOSIN.
AU3418484A (en) Diarylindane-1,3-diones
ATE89569T1 (en) HEEMOGLOBIN WITH REDUCED VIRUS RISK AND ITS MANUFACTURE.
FI885025A (en) KOAGULATIONSHAEMMANDE PROTEIN PP4-X, DESS FRAMSTAELLNING OCH ANVAENDNING.
ES8706665A1 (en) Norfloxacin salt.